The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring
Open accessAbstract
Blood biomarkers indicative of Alzheimer’s disease (AD) pathology are altered in both preclinical and symptomatic stages of the disease. Distinctive biomarkers may be optimal for the identification of AD pathology or monitoring of disease progression. Blood biomarkers that correlate with changes in cognition and atrophy during the course of the disease could be used in clinical trials to identify successful interventions and thereby accelerate the development of efficient therapies. When disease-modifying treatments become approved for use, efficient blood-based biomarkers might also inform on treatment implementation and management in clinical practice. In the BioFINDER-1 cohort, plasma phosphorylated (p)-tau231 and amyloid-β42/40 ratio were more changed at lower thresholds of amyloid pathology. Longitudinally, however, only p-tau217 demonstrated marked amyloid-dependent changes over 4–6 years in both preclinical and symptomatic stages of the disease, with no such changes observed in p-tau231, p-tau181, amyloid-β42/40, glial acidic fibrillary protein or neurofilament light. Only longitudinal increases of p-tau217 were also associated with clinical deterioration and brain atrophy in preclinical AD. The selective longitudinal increase of p-tau217 and its associations with cognitive decline and atrophy was confirmed in an independent cohort (Wisconsin Registry for Alzheimer’s Prevention). These findings support the differential association of plasma biomarkers with disease development and strongly highlight p-tau217 as a surrogate marker of disease progression in preclinical and prodromal AD, with impact for the development of new disease-modifying treatments.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures




![Extended Data Fig. 1 Associations between plasma biomarkers and CSF Aβ42/40 in BioFINDER-1 (cohort 1). Log10-transformed plasma biomarker levels were compared between the CSF Aβ42/40 quintile groups, Q1 ( > 0.102; median [MD], 0.108; n = 115, reference group), Q2 (range, 0.089-0.102; MD, 0.097; n = 115), Q3 (range 0.064-0.089; MD, 0.079; n = 115), Q4 (range, 0.042-0.064; MD, 0.051; n = 115) and Q5 (range, <0.042; MD, 0.035; n = 115) using univariate general linear models adjusting for age. Untransformed data are presented in the boxplots to aid interpretation of biomarker values across different comparisons. Outliers (p-tau217, n = 1; p-tau181, n = 2; GFAP, n = 1; NfL, n = 2) are not shown in the boxplots but were included in the statistical analysis. Boxes show interquartile range, the horizontal lines are medians, and the whiskers were plotted using Tukey method. Two-sided p-values were corrected for multiple comparisons using Benjamini–Hochberg false discovery rate; uncorrected and corrected p-values are shown in Extended Data Table 6.](/paper-figures/3d40787d09f443a79927e32c2f574cd4/differential-roles-of-a42-40-p-tau231-and-p-tau217-for-alzheimers-trial-figure-5.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology19–25, neuropathological changes associated with AD20,23,26,27 and the subsequent development of AD dementia20,23,28.”
From Highly accurate blood test for Alzheimer's disease is similar or superior to clinical cerebrospinal fluid tests (2024) · cites this paper as [19]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Additionally, p-tau217 demonstrates a unique longitudinal trajectory, showing increases associated with worsening brain atrophy and declining cognitive performance in individuals with elevated Aβ pathology.24,25”
From Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology (2024) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Palmqvist, S., Janelidze, S., Quiroz, Y. T., Zetterberg, H., Lopera, F., Stomrud, E., Su, Y., Chen, Y., Serrano, G. E., Leuzy, A., et al. (2020) · JAMA · doi:10.1001/jama.2020.12134 · Cited by 1,603
Self-citationThe Centiloid Project: standardizing quantitative amyloid plaque estimation by PET
Klunk, W. E., Koeppe, R. A., Price, J. C., Benzinger, T. L., Devous, M. D., Jagust, W. J., Johnson, K. A., Mathis, C. A., Minhas, D., Pontecorvo, M. J., et al. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.07.003 · Cited by 1,348
Karikari, T. K., Pascoal, T. A., Ashton, N. J., Janelidze, S., Benedet, A. L., Rodriguez, J. L., Chamoun, M., Savard, M., Kang, M. S., Therriault, J., et al. (2020) · The Lancet Neurology · doi:10.1016/s1474-4422(20)30071-5 · Cited by 1,316
Self-citationJanelidze, S., Mattsson, N., Palmqvist, S., Smith, R., Beach, T. G., Serrano, G. E., Chai, X., Proctor, N. K., Eichenlaub, U., Zetterberg, H., et al. (2020) · Nature Medicine · doi:10.1038/s41591-020-0755-1 · Cited by 1,247
Self-citationBiomarkers for neurodegenerative diseases
Hansson, O. (2021) · Nature Medicine · doi:10.1038/s41591-021-01382-x · Cited by 1,159
Self-citationAssociation of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease
Mattsson, N., Andreasson, U., Zetterberg, H., Blennow, K., & Initiative, F. T. A. D. N. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6117 · Cited by 1,070
Self-citationDefining imaging biomarker cut points for brain aging and Alzheimer's disease
Jack, C. R., Wiste, H. J., Weigand, S. D., Therneau, T. M., Lowe, V. J., Knopman, D. S., Gunter, J. L., Senjem, M. L., Jones, D. T., Kantarci, K., et al. (2017) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2016.08.005 · Cited by 931
High-precision plasma β-amyloid 42/40 predicts current and future brain amyloidosis
Schindler, S. E., Bollinger, J. G., Ovod, V., Mawuenyega, K. G., Li, Y., Gordon, B. A., Holtzman, D. M., Morris, J. C., Benzinger, T. L. S., Xiong, C., et al. (2019) · Neurology · doi:10.1212/wnl.0000000000008081 · Cited by 885
Self-citationThe Preclinical Alzheimer Cognitive Composite: Measuring Amyloid-Related Decline
Donohue, M. C., Sperling, R. A., Salmon, D. P., Rentz, D. M., Raman, R., Thomas, R. G., Weiner, M., & Aisen, P. S. (2014) · JAMA Neurology · doi:10.1001/jamaneurol.2014.803 · Cited by 860
Mattsson, N., Cullen, N. C., Andreasson, U., Zetterberg, H., & Blennow, K. (2019) · JAMA Neurology · doi:10.1001/jamaneurol.2019.0765 · Cited by 726
Self-citation
Cited by
Diagnostic Accuracy of a Plasma Phosphorylated Tau 217 Immunoassay for Alzheimer Disease Pathology
Ashton, N. J., Brum, W. S., Di Molfetta, G., Benedet, A. L., Arslan, B., Jonaitis, E., Langhough, R. E., Cody, K., Wilson, R., Carlsson, C. M., et al. (2024) · JAMA Neurology · doi:10.1001/jamaneurol.2023.5319 · Cited by 884
Self-citationBlood biomarkers for Alzheimer’s disease in clinical practice and trials
Hansson, O., Blennow, K., Zetterberg, H., & Dage, J. (2023) · Nature Aging · doi:10.1038/s43587-023-00403-3 · Cited by 522
Self-citationBarthélemy, N. R., Salvadó, G., Schindler, S. E., He, Y., Janelidze, S., Collij, L. E., Saef, B., Henson, R. L., Chen, C. D., Gordon, B. A., et al. (2024) · Nature Medicine · doi:10.1038/s41591-024-02869-z · Cited by 448
“Plasma levels of p-tau are strongly associated with PET and CSF biomarkers of AD pathology 19–25 , neuropathological changes associated with AD 20,23,26,27 and the subsequent development of AD dementia 20,23,28 .”
BackgroundSelf-citationAlzheimer's disease: From immunotherapy to immunoprevention
Jucker, M., & Walker, L. C. (2023) · Cell · doi:10.1016/j.cell.2023.08.021 · Cited by 353
Plasma proteomic profiles predict future dementia in healthy adults
Guo, Y., You, J., Zhang, Y., Liu, W.-S., Huang, Y.-Y., Zhang, Y.-R., Zhang, W., Dong, Q., Feng, J.-F., Cheng, W., et al. (2024) · Nature Aging · doi:10.1038/s43587-023-00565-0 · Cited by 293
Metadata
- Authors
- Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., Jonaitis, E. M., Koscik, R. L., Cody, K., Betthauser, T. J., Li, Y., Vanmechelen, E., Palmqvist, S., Stomrud, E., Bateman, R. J., Zetterberg, H., Johnson, S. C., Blennow, K., & Hansson, O.
- Affiliations
- King's College London (GB)
- Lund University (SE)
- Universidade Federal do Rio Grande do Sul (BR)
- University of Pittsburgh (US)
- University of Gothenburg (SE)
- University of Wisconsin–Madison (US)
- Washington University in St. Louis (US)
- ADx NeuroSciences (BE)
- Sahlgrenska University Hospital (SE)
- Corresponding author
- Blennow, Kaj
- Hansson, Oskar
- ORCID
- Ashton, Nicholas J.
- Janelidze, Shorena
- Binette, Alexa Pichet
- Brum, Wagner S.
- Karikari, Thomas K.
- Meda, Francisco J.
- Jonaitis, Erin M.
- Koscik, Rebecca Langhough
- Cody, Karly
- Betthauser, Tobey J.
- Vanmechelen, Eugeen
- Palmqvist, Sebastian
- Stomrud, Erik
- Bateman, Randall J.
- Zetterberg, Henrik
- Johnson, Sterling C.
- Blennow, Kaj
- Hansson, Oskar
- Venue
- Nature Medicine
- Published
- 2022-12
- Volume
- 28
- Issue
- 12
- Pages
- 2555-2562
- ISSN
- 1078-8956 (ISSN-L)
- 1546-170X
- PMC
- PMC9800279
- OpenAlex
- W4310603866
- Cited by
- 436
- References
- 53
- Citations by year
- 2026: 99 · 2025: 128 · 2024: 135 · 2023: 72 · 2022: 1
- FWCI
- 52.02
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- creativecommons.org/licenses/by/4.0 (tdm)
- creativecommons.org/licenses/by/4.0 (vor)
- Locations
- Nature Medicine (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion, cc-by)
- UCL Discovery (University College London) (submittedVersion)
- Lund University Publications (Lund University) (submittedVersion)
- Funders
- Alzheimer's Association (ADSF-21-831377-C, ZEN-21-848495, ADSF‐21‐831376‐C, ADSF-21-831376-C, ADSF-21-831381-C and ADSF-21-831377-C, #ADSF-21-831381-C, 2021 Zenith Award, -21- 831377-C)
- Alzheimer's Drug Discovery Foundation (201809–2016862, 201809-2016615, #RDAPB‐201809‐2016615)
- Eli Lilly and Company
- Pfizer
- Biogen
- Familjen Erling-Perssons Stiftelse (FO2019-0228, 860197)
- Stiftelsen för Gamla Tjänarinnor (860197, FO2019‐0228)
- EU Joint Programme – Neurodegenerative Disease Research (JPND2019-466-236)
- Prothena
- Australian Government
- Cerveau Technologies
- European Commission (HORIZON2020, JPND2019‐466‐236, 860197)
- Lunds Universitet
- Eisai
- Hjärnfonden (FO2019-0029, ALZ2022-0006), FO2021-0293, FO2017‑0243, FO2017, ALFGBG-715986, FO2020‐0271, FO2019‐0228, #ALFGBG-965240, JPND2019-466-236)
- Knut och Alice Wallenbergs Stiftelse (681712, 2017‐0383)
- Vetenskapsrådet (ALFGBG-965240, ALZ2022-0006, 2017-00915, 2016-00906, (#ALFGBG-715986, 681712, FO2021-0293, 2018-, JPND2019-466-236, 2018-02052, 2021-02219, 2017-00383, FO2017-0243, 2018-02532)
- Konung Gustaf V:s och Drottning Victorias Frimurarestiftelse (2020-O000028, 2020-0314, FO2017-0243)
- Region Skåne
- Skånes universitetssjukhus (2020-O000028)
- Siemens Healthineers
- Marcus och Amalia Wallenbergs minnesfond (2015.0125)
- Julius Clinical
- UK Dementia Research Institute (#2017-00915)
- Olav Thon Stiftelsen (#FO2019-0228)
- Stiftelsen Bundy Academy
- National Institutes of Health (ZEN-21- 848495, AG027161)
- Genentech
- Parkinsonfonden (1280/20)
- Avid Radiopharmaceuticals
- National Institute on Aging (R01AG068398, RF1AG027161, R01AG021155, R01AG027161, P30AG062715)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Amyotrophic Lateral Sclerosis Research
- Keywords
- Alzheimer's disease, blood biomarkers, phosphorylated tau217, preclinical Alzheimer's disease, prodromal Alzheimer's disease, disease progression, brain atrophy, cognitive decline, disease-modifying therapy, clinical trial selection, neurofilament light chain, Wisconsin Registry for Alzheimer's Prevention
- MeSH terms
- Alzheimer Disease, Atrophy, Humans, Peptide Fragments, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Cognitive Dysfunction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. https://app.cochat.ai/papers/10.1038/s41591-022-02074-w
- The paper
- Ashton, N. J., Janelidze, S., Mattsson-Carlgren, N., Binette, A. P., Strandberg, O., Brum, W. S., Karikari, T. K., González-Ortiz, F., Di Molfetta, G., Meda, F. J., Jonaitis, E. M., Koscik, R. L., Cody, K., Betthauser, T. J., Li, Y., Vanmechelen, E., Palmqvist, S., Stomrud, E., Bateman, R. J., . . . Hansson, O. (2022). Differential roles of Aβ42/40, p-tau231 and p-tau217 for Alzheimer’s trial selection and disease monitoring. Nature Medicine. https://doi.org/10.1038/s41591-022-02074-w
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.